Artinis & NIRx become one organisation to accelerate the future of neuroscience research
Two pioneers of fNIRS and EEG solutions unite as a single product-led team, expanding the portfolio, scale, and support available to brain and body researchers worldwide
Elst, the Netherlands, & Berlin, Germany — 3 June 2026 — Artinis Medical Systems and NIRx Medical Technologies, two of the world's leading developers of functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) technology, today announced that they are operating as one organisation, Artinis & NIRx. This builds on the acquisitions of both companies by specialist healthcare investor Gilde Healthcare in 2025. The merger unites the two businesses behind a single mission: to help more researchers conduct more neuroscience experiments, create knowledge, and publish their findings.
Where the companies previously operated as complementary brands under shared ownership, they now operate as one business with a joined-up, customer-focused organisation. The business is an R&D powerhouse with a unified strategy, a newly established one-company product team, and one product roadmap.
The combined organisation brings together Artinis' wearable fNIRS heritage and NIRx's high-fidelity research systems, together with TMSi’s EEG solutions (acquired by Artinis in 2024). The individual product brands will continue within the broadest portfolio available in the field, from compact wearable devices for real-world and movement studies to lab-based and high-density systems, including hyperscanning, infant research, and integration of fNIRS, EEG, fMRI, TMS, and eye-tracking.
Both companies were founded over twenty years ago by academics and grew up in the same field. That shared history — and a shared obsession with great products, rigorous science, and outstanding researcher support — is the foundation for the new organisation. The founders and leaders of both companies remain actively involved, leading and advising the business.
Rather than scaling back, the combined organisation is investing and growing, increasing overall headcount and expanding the capacity available to support its growing global community of academic and applied-research users. Customers will continue to work with the products, teams, and contacts they already know, with continuity of service throughout the transition.
“fNIRS is still in its early stages while EEG use is more widespread. Bringing Artinis and NIRx together as one team means we can give researchers a more complete toolkit – from wearable systems in the real world to high-fidelity systems for the lab – and innovate faster with a sizeable joined-up R&D team.”
The combined organisation will continue to operate from its existing locations, including Elst & Oldenzaal (the Netherlands), Berlin (Germany), and Orlando (United States).